Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model

The immune system, and in particular, cytotoxic CD8+ T cells (CTLs), plays a vital part in the prevention and elimination of tumors. In many patients, however, CTL-mediated tumor killing ultimately fails in the clearance of cancer cells resulting in disease progression, in large part due to the progression of effector CTL into exhausted CTL. While there have been major breakthroughs in the development of CTL-mediated “reinvigoration”-driven immunotherapies such as checkpoint blockade therapy, there remains a need to better understand the drivers behind the development of T cell exhaustion. Our study highlights the unique differences in T cell exhaustion development in tumor-specific CTL which arises over time in a mouse model of mesothelioma. Importantly, we also show that peripheral tumor-specific T cells have a unique expression profile compared to exhausted tumor-infiltrating CTL at a late-stage of tumor progression in mice. Together, these data suggest that greater emphasis should be placed on understanding contributions of individual microenvironments in the development of T cell exhaustion.

[1]  E. Wherry,et al.  CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. , 2019, Annual review of immunology.

[2]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[3]  O. Lantz,et al.  Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node , 2018, Nature Communications.

[4]  T. Schumacher,et al.  T Cell Dysfunction in Cancer. , 2018, Cancer cell.

[5]  A. Ribas,et al.  Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) , 2017, The Lancet.

[6]  Chiun-Sheng Huang,et al.  TGF‐β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up‐regulation of IL‐17RB , 2017, EMBO molecular medicine.

[7]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[8]  Tithi Ghosh,et al.  Tumor promoting role of anti-tumor macrophages in tumor microenvironment. , 2017, Cellular immunology.

[9]  B. Stanger,et al.  Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. , 2016, JCI insight.

[10]  M. Delorenzi,et al.  High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival , 2016, The Journal of experimental medicine.

[11]  E. Elkord,et al.  Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting , 2016, Vaccines.

[12]  D. Nelson,et al.  Murine mesothelioma induces locally-proliferating IL-10+TNF-α+CD206−CX3CR1+ M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy , 2016, Oncoimmunology.

[13]  J. Ahn,et al.  Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.

[14]  A. Madi,et al.  TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection , 2016, PLoS pathogens.

[15]  A. Arina,et al.  Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. , 2016, Seminars in immunology.

[16]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American journal of clinical oncology.

[17]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[19]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[20]  C. Mamotte,et al.  Mesothelioma Tumor Cells Modulate Dendritic Cell Lipid Content, Phenotype and Function , 2015, PloS one.

[21]  John J. Erickson,et al.  Programmed Death-1 Impairs Secondary Effector Lung CD8+ T Cells during Respiratory Virus Reinfection , 2014, The Journal of Immunology.

[22]  M. King,et al.  Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy , 2014, International journal of molecular sciences.

[23]  A. Farina,et al.  CD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression , 2014, PLoS pathogens.

[24]  O. Lund,et al.  T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection , 2014, PLoS pathogens.

[25]  Xuetao Cao,et al.  Human hepatocellular carcinoma-infiltrating CD4+CD69+Foxp3− regulatory T cell suppresses T cell response via membrane-bound TGF-β1 , 2014, Journal of Molecular Medicine.

[26]  Mark G. Lewis,et al.  Type I Interferon Upregulates Bak and Contributes to T Cell Loss during Human Immunodeficiency Virus (HIV) Infection , 2013, PLoS pathogens.

[27]  T. Padera,et al.  Lymphatic function and immune regulation in health and disease. , 2013, Lymphatic research and biology.

[28]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[29]  C. Thompson,et al.  At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy , 2013, Journal of leukocyte biology.

[30]  G. Freeman,et al.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. , 2013, Cancer research.

[31]  Burton E. Barnett,et al.  Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection , 2012, Science.

[32]  A. Oxenius,et al.  Antigen amount dictates CD8+ T‐cell exhaustion during chronic viral infection irrespective of the type of antigen presenting cell , 2012, European journal of immunology.

[33]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[34]  E John Wherry,et al.  T cell exhaustion , 2011 .

[35]  D. Dolfi,et al.  Dendritic Cells and CD28 Costimulation Are Required To Sustain Virus-Specific CD8+ T Cell Responses during the Effector Phase In Vivo , 2011, The Journal of Immunology.

[36]  Mario Roederer,et al.  SPICE: Exploration and analysis of post‐cytometric complex multivariate datasets , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[37]  J. Mulligan,et al.  Tumors induce the formation of suppressor endothelial cells in vivo , 2010, Cancer Immunology, Immunotherapy.

[38]  P. Katsikis,et al.  Chronic Antigen Stimulation Alone Is Sufficient to Drive CD8+ T Cell Exhaustion1 , 2009, The Journal of Immunology.

[39]  S. Cornwall,et al.  Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells , 2009, European Respiratory Journal.

[40]  R. Zheng,et al.  Tumor-Induced CD11b+Gr-1+ Myeloid Cells Suppress T Cell Sensitization in Tumor-Draining Lymph Nodes1 , 2008, The Journal of Immunology.

[41]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[42]  D. Sojka,et al.  Mechanisms of regulatory T‐cell suppression – a diverse arsenal for a moving target , 2008, Immunology.

[43]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[44]  S. Szabo,et al.  Antigen-driven effector CD8 T cell function regulated by T-bet , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Robinson,et al.  IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2 1 , 2003, The Journal of Immunology.

[46]  Hao Shen,et al.  Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin , 2003, Science.

[47]  J. Altman,et al.  Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells. , 2001, Immunity.

[48]  Saroja Ramanujan,et al.  Differential Dynamics of CD4+ and CD8+ T-Lymphocyte Proliferation and Activation in Acute Simian Immunodeficiency Virus Infection , 2000, Journal of Virology.

[49]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[50]  Kristin A. Hogquist,et al.  T cell receptor antagonist peptides induce positive selection , 1994, Cell.

[51]  D. Wiley,et al.  HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American Journal of Clinical Oncology.

[53]  Taeg S. Kim,et al.  The effector T cell response to influenza infection. , 2015, Current topics in microbiology and immunology.

[54]  A. Liston,et al.  Regulatory T Cells , 2011, Methods in Molecular Biology.